Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-04-09
2008-03-11
Navarro, Mark (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S190100
Reexamination Certificate
active
07341843
ABSTRACT:
The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance tobotulinumtoxin therapy in an individual using BoNT/A peptides.
REFERENCES:
patent: 4551435 (1985-11-01), Liberti et al.
patent: 4643718 (1987-02-01), Marten
patent: 5731161 (1998-03-01), Aoki et al.
patent: 6048529 (2000-04-01), Atassi et al.
patent: 6136551 (2000-10-01), Aoki et al.
patent: 6287566 (2001-09-01), Dertzbaugh
patent: 6667158 (2003-12-01), Bavari et al.
patent: 6676622 (2004-01-01), Strahilevitz
patent: 2002/0155114 (2002-10-01), Marks et al.
patent: 2002/0197278 (2002-12-01), Allison
patent: 2004/0101534 (2004-05-01), Diamond
patent: 2004/0110284 (2004-06-01), Bavari et al.
patent: 2004/0175385 (2004-09-01), Marks et al.
patent: 2005/0106182 (2005-05-01), Li et al.
patent: 94/21684 (1994-09-01), None
patent: 2005014798 (2005-02-01), None
Bavari, S et al, Vaccine, vol. 16(19), pp. 1850-1856, 1998, Identifying the principal protective antigenic determinants of type A botulinum neurotoxin.
Dertzbaugh, Mark T et al, Vaccine, vol. 14(16), pp. 1538-1544, 1996, Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum.
Kozaki, Shunji et al, Infection and Immunity, Jun. 1986, vol. 52(3), pp. 786-791, The use of monoclonal antibodies to analyze the structure ofClostridium botulinumtype E derivative toxin.
Kubota, T et al, Appl. Environ. Microbiol., Apr. 1997, vol. 63(4), pp. 1214-1218, Epitope regions in teh Heavy chain ofClostridium botulinumType E neurotoxin by monoclonal antibodies.
Harlow et al, Monoclonal antibodies (reference of record).
Oshima, M et al, Immunology Letters, vol. 60, pp. 7-12, Jan. 1998.
Oshima, M e tal, Molecular Immunology, vol. 34(14), pp. 1031-1040, 1997, Immune recognition of botulinum neurotoxin type A: Regions recognized by T cells and antibodies against the protective Hc fragemtn residues 855-1296 of the toxin.
Rosenberg, JA et al, Immunological Investigations, vol. 26(4), pp. 491-504, 1997, Localization of the regions on the C-terminal domain of the heavy chain of botulinum toxin A by T lymphocytes and by antibodies after immunization of mice with pentavalent.
Naumann et al (1998), Immunol. Letters. reference of record.
Singh et al, Toxicon, 1996, vol. 36(2) pp. 267-275, reference of record.
Atassi, M. Z, Scientific and Therapeutic Aspects of Botulinum toxins, Chapter 38, pp. 385-407.
Dertzbaugh, MT et al, Vaccine, vol. 14(16), pp. 538-1544, 1996, Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum.
Lacy, D. B et al, Journal of Molecular Biology, vol. 291, pp. 1091-1104, 1999, Sequence homology and structural analysis of the Clostridial neurotoxins.
Lebeda, Frank J. et al, Journal of Protein Chemistry, vol. 16(6), pp. 607-618, 1997., Predicint Differential antigen-antibody contact regions based on solvent accessibility.
Byrne, MP e al, Biochimie, vol. 82, pp. 955-966, 2000, Development of vaccines for prevention of botulism.
Raju, R et al, Joural of autoimmunity, vol. 9, pp. 79-83, 1996, Epitope repertoire of Human CD4+ lines propagated with Tetanus toxoid or with synthetic tetanus toxin sequences.
Oblatt-Montal, M et al, Protein Science, vol. 4, pp. 1490-1497, 1995, Formation of ion channels in lipid bilayers by a peptide with the predicted transmembrane sequence of botulinum neurotoxin A.
Oblatt-Montal et al, Protein Science, 1995, pp. 1490-1497, vol. 4.
Raju, R et al, J. of autoimmunity, vol. 9, pp. 79-88, 1996.
Atassi, M. Zouhair, Scientific and Therapeutic Aspects of Botulinum toxin, chapter 38, pp. 385-407.
Oshima, Minako et al, Immunology Letters, vol. 60, pp. 7-12, 1998.
Oshima, Minako et al, Molecular Immunology, vol. 34(14), pp. 1031-1040, 1997.
Tugnoli, V et al, Expert. Opinion Investig. Drugs, Oct. 1997, vol. 6(10), pp. 1383-1394.
Dolimbek, BZ et al, Molecular Immunology, vol. 44, pp. 1029-1041, 2007, available on line May 2, 2006.
Jankovic, Joseph, MD et al, Neurology, vol. 45(9), pp. 1743-1746, Sep. 1995.
Hanna, Philip A. MD et al, Neurology, vol. 50(6), pp. 1624-1629, Jun. 1998.
Krieglstein, Kerstin G et al, Journal of protein Chemistry, vol. 13(1), apges 49-57, 1994.
Beecher, DJ et al, J. Protein Chemistry, vol. 16(7), pp. 701-712, 1997.
Swiss Prot Accession No. Q97TT9, Oct. 1, 2001, Gibson et al (sequence alignment provided).
Swiss Prot sequence Q9PRU1, May 1, 2000, Kikuyama et al, sequence alignment provided.
Swiss Prot sequence Q8KHN9, Oct. 1, 2002, Dineen et al, sequence alignment provided.
Amersdorfer et al., “Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries,”Vaccine20:1640-1648 (2002).
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,”Infect. Immun. 65:3743-3752 (1997).
Aoki, “Pharmacology and immunology of botulinum toxin serotypes,”J. Neurol. 248 Suppl. 1:3-10 (2001).
Atassi and Dolimbek, “Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A,”Protein J. 23:39-52 (2004).
Atassi and Oshima, “Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins,”Crit. Revs. Immunol. 19:219-260 (1999).
Atassi and Smith, “A proposal for the nomenclature of antigenic sites in peptides and proteins,”Immunochemistry15:609-610 (1978).
Atassi et al., “Cross-reaction of mouse antibodies against Tetanus neurotoxin with Botulinum neurotoxins A and B,”International Conference 2002, Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, Jun. 8-12, Abstract R12 (2002).
Atassi et al., “Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor,”Proc. Natl. Acad. Sci. USA88:3613-3617 (1991).
Atassi et al., “Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species,”J. Prot. Chem. 15:691-700 (1996).
Atassi, “Immune recognition and cross-reactivity of botulinum neurotoxins,” inScientific and Therapeutic Aspects of Botulinum Toxins(edited by Brin et al.), pp. 385-408, Lippincott Williams and Wilkins, Philadelphia, PA (2002).
Bavari et al., “Identifying the principal protective antigenic determinants of type A botulinum neurotoxin,”Vaccine16:1850-1856 (1998).
Cenci Di Bello et al., “Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes,”Eur. J. Biochem. 219:161-169 (1994).
Chen et al., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,”Infect. Immun. 65:1626-1630 (1997).
Clayton and Middlebrook, “Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A,”Vaccine18:1855-1862 (2000).
Clayton et al., “Protective vaccination with a recombinant fragment ofClostridium botulinumneurotoxin serotype A expressed from a synthetic gene inEscherichia coli,”Infect. Immun. 63:2738-2742 (1995).
Dertzbaugh and West, “Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum,”Vaccine14:1538-1544 (1996).
Dolimbek and Atassi, “Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides,”Mol. Immunol. 33:681-689 (1996).
Dolimbek et al., “Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response,”Immunological Investigations31:247-262 (2002).
Dressler et al., “Antibody-induced botulinum toxin therapy failure: Can it be overcome by increased botul
Allergan Inc.
German Joel B.
Navarro Mark
Portner Ginny Allen
Stathakis Dean G.
LandOfFree
Botulinum toxin A peptides and methods of predicting and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin A peptides and methods of predicting and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin A peptides and methods of predicting and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967507